康方生物-话题@MedSci

#康方生物#

7篇内容 | 1228人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2248100, encodeId=75292248100b9, content=<a href='/topic/show?id=ac55e188816' target=_blank style='color:#2F92EE;'>#百济神州#</a> <a href='/topic/show?id=f0a94946ebd' target=_blank style='color:#2F92EE;'>#康方生物#</a> <a href='/topic/show?id=7b6f123324a4' target=_blank style='color:#2F92EE;'>#J.P.Morgan健康大会#</a>, objectTitle=JPM25：中国药企表现亮眼，国际巨头发布2025年展望, objectType=article, longId=859609, objectId=21e485960957, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20241101/eb2c50d70d364d8ebb95feb227937e6e-PVwoXIuwlAFu.jpg, objectUrl=/article/show_article.do?id=21e485960957, replyNumber=0, likeNumber=34, createdTime=2025-01-15, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=美国, moduleDTOList=[ModuleDTO(moduleId=21e485960957, moduleTitle=JPM25：中国药企表现亮眼，国际巨头发布2025年展望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21e485960957)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2156980, encodeId=f75721569801c, content=<a href='/topic/show?id=ec5d10661385' target=_blank style='color:#2F92EE;'>#cadonilimab#</a><a href='/topic/show?id=f0a94946ebd' target=_blank style='color:#2F92EE;'>#康方生物#</a>, objectTitle=Lung Cancer：双免疫新药卡度尼利二线治疗NSCLC的临床试验失败（AK104-202研究）, objectType=article, longId=790963, objectId=7f86e9096395, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230910/1694307022900_4754896.png, objectUrl=/article/show_article.do?id=7f86e9096395, replyNumber=0, likeNumber=96, createdTime=2023-09-10, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=7f86e9096395, moduleTitle=Lung Cancer：双免疫新药卡度尼利二线治疗NSCLC的临床试验失败（AK104-202研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f86e9096395)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1981337, encodeId=43e8198133eaf, content=<a href='/topic/show?id=f0a94946ebd' target=_blank style='color:#2F92EE;'>#康方生物#</a>, objectTitle=康方生物AK120获美国FDA批准特应性皮炎全球Ⅱ期临床试验, objectType=article, longId=217821, objectId=08dd21e8212d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08dd21e8212d, replyNumber=0, likeNumber=91, createdTime=2022-07-16, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08dd21e8212d, moduleTitle=康方生物AK120获美国FDA批准特应性皮炎全球Ⅱ期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08dd21e8212d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1981334, encodeId=d33e1981334c3, content=<a href='/topic/show?id=f0a94946ebd' target=_blank style='color:#2F92EE;'>#康方生物#</a>, objectTitle=全球首创！康方生物PD-1/CTLA-4双抗治疗宫颈癌获美国FDA孤儿药认定, objectType=article, longId=207633, objectId=bf5620e63327, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf5620e63327, replyNumber=0, likeNumber=76, createdTime=2022-01-24, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf5620e63327, moduleTitle=全球首创！康方生物PD-1/CTLA-4双抗治疗宫颈癌获美国FDA孤儿药认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf5620e63327)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1981335, encodeId=598119813353b, content=<a href='/topic/show?id=f0a94946ebd' target=_blank style='color:#2F92EE;'>#康方生物#</a>, objectTitle=康方生物PD-1获FDA突破性疗法资格，三线治疗转移性鼻咽癌, objectType=article, longId=209532, objectId=d4c8209532bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4c8209532bd, replyNumber=0, likeNumber=109, createdTime=2022-03-15, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4c8209532bd, moduleTitle=康方生物PD-1获FDA突破性疗法资格，三线治疗转移性鼻咽癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4c8209532bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1981336, encodeId=38521981336e3, content=<a href='/topic/show?id=f0a94946ebd' target=_blank style='color:#2F92EE;'>#康方生物#</a>, objectTitle=PD-1/L1竞争再加剧，中国生物制药与康方生物研发的治疗鼻咽癌新药上市申请获国家药监局受理, objectType=article, longId=215388, objectId=bc0f21538845, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc0f21538845, replyNumber=0, likeNumber=101, createdTime=2021-10-13, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc0f21538845, moduleTitle=PD-1/L1竞争再加剧，中国生物制药与康方生物研发的治疗鼻咽癌新药上市申请获国家药监局受理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc0f21538845)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1981332, encodeId=285c1981332e2, content=<a href='/topic/show?id=f0a94946ebd' target=_blank style='color:#2F92EE;'>#康方生物#</a>, objectTitle=康方生物免疫治疗性抗体AK101获得溃疡性结肠炎临床试验批件, objectType=article, longId=194209, objectId=0c06194209e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c06194209e6, replyNumber=0, likeNumber=97, createdTime=2021-03-21, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c06194209e6, moduleTitle=康方生物免疫治疗性抗体AK101获得溃疡性结肠炎临床试验批件, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c06194209e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1981333, encodeId=c566198133359, content=<a href='/topic/show?id=f0a94946ebd' target=_blank style='color:#2F92EE;'>#康方生物#</a>, objectTitle=康方生物抗PD-1/CTLA-4双特异性抗体治疗转移性宫颈癌，获得FDA快速指定, objectType=article, longId=199753, objectId=c938199e53cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c938199e53cd, replyNumber=0, likeNumber=87, createdTime=2021-06-28, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c938199e53cd, moduleTitle=康方生物抗PD-1/CTLA-4双特异性抗体治疗转移性宫颈癌，获得FDA快速指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c938199e53cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

康方生物

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#百济神州# #康方生物# #J.P.Morgan健康大会#

JPM25：中国药企表现亮眼，国际巨头发布2025年展望

2025-01-15发表于美国

侠胆医心 (审核中...)

前往app查看评论内容

#cadonilimab##康方生物#

Lung Cancer：双免疫新药卡度尼利二线治疗NSCLC的临床试验失败（AK104-202研究）

2023-09-10发表于上海

hb2008ye (审核中...)

前往app查看评论内容

#康方生物#

康方生物AK120获美国FDA批准特应性皮炎全球Ⅱ期临床试验

2022-07-16

hb2008ye (审核中...)

前往app查看评论内容

#康方生物#

全球首创！康方生物PD-1/CTLA-4双抗治疗宫颈癌获美国FDA孤儿药认定

2022-01-24

hb2008ye (审核中...)

前往app查看评论内容

#康方生物#

康方生物PD-1获FDA突破性疗法资格，三线治疗转移性鼻咽癌

2022-03-15

hb2008ye (审核中...)

前往app查看评论内容

#康方生物#

PD-1/L1竞争再加剧，中国生物制药与康方生物研发的治疗鼻咽癌新药上市申请获国家药监局受理

2021-10-13

hb2008ye (审核中...)

前往app查看评论内容

#康方生物#

康方生物免疫治疗性抗体AK101获得溃疡性结肠炎临床试验批件

2021-03-21

hb2008ye (审核中...)

前往app查看评论内容

#康方生物#

康方生物抗PD-1/CTLA-4双特异性抗体治疗转移性宫颈癌，获得FDA快速指定

2021-06-28

科室
- - 订阅+
  - 更多科室
工具
服务